comparemela.com

Latest Breaking News On - Oncology biosimilar - Page 1 : comparemela.com

Fresenius : Conference Call Q1/2024 - MarketScreener

Fresenius : Conference Call Q1/2024 - MarketScreener
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Coherus BioSciences (NYSE:CHRS) - Coherus BioSciences: Q1 Earnings Insights

52-week low: $13.53 Company Description Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.   Related Articles (CHRS)

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.